Trials / Unknown
UnknownNCT05762458
The Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression
Efficacy and Safety of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase Ⅱ Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 240 (estimated)
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of Ammoxetine hydrochloride enteric-coated tablets in subjects with depression.
Detailed description
In this study, a randomized, double-blind, placebo-controlled multicenter study will be conducted to evaluate the efficacy and safety of different doses of Ammoxetine hydrochloride enteric coated tablets in the treatment of depression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ammoxetine | Ammoxetine hydrochloride enteric-coated tablets |
| DRUG | Placebo | placebo to Ammoxetine. |
Timeline
- Start date
- 2023-02-28
- Primary completion
- 2024-05-15
- Completion
- 2024-10-15
- First posted
- 2023-03-09
- Last updated
- 2023-03-09
Source: ClinicalTrials.gov record NCT05762458. Inclusion in this directory is not an endorsement.